{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000059","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.735545+00:00","generated_at":"2026-05-22T18:07:43.541529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immuneering reports Q1 2025 results: net loss $15M, positive IMM-1-104 data, CMO named","bullets":["Net loss $15.0M ($0.42/sh) vs $14.3M ($0.49/sh) in Q1 2024; R&D expenses $11.5M.","Cash $35.9M as of March 31, 2025; runway extended into 2026.","Positive IMM-1-104 data: 13-month monotherapy PFS in third-line pancreatic cancer; complete response in first-line combo with chemo.","Named Dr. Igor Matushansky as CMO; signed clinical supply agreement with Regeneron for Libtayo combo in NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000059","json":"https://secwatch.observer/filing/0001790340-25-000059.json","markdown":"https://secwatch.observer/filing/0001790340-25-000059.md","text":"https://secwatch.observer/filing/0001790340-25-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/0001790340-25-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000059/imrx-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T18:07:43.541529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}